Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and Prognostic Applications of PET/CT in Small-cell Lung Cancer.

Cancer diagnosis & prognosis·2026
Same author

Tracing genome size dynamics in sharks and rays with inclusive sequence analysis by the Squalomix Consortium.

Genome research·2026
Same author

Clinical Value of a Novel Apparent Diffusion Coefficient-Based Bi-Color Map for Detecting Clinically Significant Prostate Cancer: A Retrospective Study.

Cancers·2026
Same author

Dosimetric and clinical outcomes of stereotactic body radiotherapy for primary lung cancer: isocenter-based vs. volume-based prescription.

Frontiers in medicine·2026
Same author

Transcatheter arterial microembolization for refractory chronic pain associated with familial gouty tophi: a case report with 2-year follow-up.

CVIR endovascular·2026
Same author

Visualization of Cranial Nerves in the Orbit Using Fat-Suppressed 3D FLAIR MR Imaging.

AJNR. American journal of neuroradiology·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Yuta Inagawa1, Yuki Miyagi1, Shoya Inagawa1

  • 1Tokyo Medical University, Shinjuku-ku, Tokyo, Japan.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Lecanemab treatment significantly reduced brain atrophy in Alzheimer

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroimaging
  • Neurology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) diagnosis relies on imaging tools like Voxel-based Specific Regional Analysis (VSRAD).
  • Assessing structural brain changes is crucial for understanding AD progression and treatment efficacy.
  • Lecanemab is an emerging therapeutic agent for AD.

Purpose of the Study:

  • To evaluate the impact of lecanemab on brain atrophy, specifically in the hippocampus and overall brain volume.
  • To utilize VSRAD imaging to quantify these changes in patients with probable AD.

Main Methods:

  • 16 patients with probable Alzheimer's disease were included.
  • Voxel-based Specific Regional Analysis (VSRAD) software was used to assess brain atrophy.
  • Changes in medial temporal cortex (hippocampus, amygdala, olfactory cortex) atrophy were measured before and after lecanemab treatment.

Main Results:

  • A statistically significant reduction in the severity of medial temporal cortex atrophy was observed after lecanemab treatment (p < 0.001).
  • The ratio of medial temporal cortex atrophy to whole brain atrophy also significantly decreased (p < 0.05).
  • These findings indicate a positive effect of lecanemab on reducing regional and overall brain atrophy.

Conclusions:

  • Lecanemab treatment led to a significant decrease in brain atrophy as measured by VSRAD.
  • The study demonstrates the potential of lecanemab in mitigating structural brain changes associated with Alzheimer's disease in clinical practice.